Vivos Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Vivos Therapeutics

25/11/2022 21:31

* Vivos Therapeutics Inc  VVOS.OQ   VVOS.O  is expected
to show a
fall in quarterly revenue when it reports  results on November
28 (estimated). 
    * The Littleton Colorado-based  company is expected to
report  a
15.3% decrease in revenue to $3.809 million from $4.5 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Vivos Therapeutics
Inc is
for a loss of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vivos
Therapeutics Inc is $4.5​, above​ its last closing price
of $0.60. ​​​

This summary was machine generated November 25 at 21:31 GMT. 
All figures in US dollars  unless otherwise stated